{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T18:48:22Z","timestamp":1791830902964,"version":"4.3.4"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T00:00:00Z","timestamp":1782086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T00:00:00Z","timestamp":1782172800000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82172666"],"award-info":[{"award-number":["82172666"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82473577"],"award-info":[{"award-number":["82473577"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"DOI":"10.1186\/s12967-026-08323-7","type":"journal-article","created":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T17:28:22Z","timestamp":1782149302000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Nrf2 deficiency converts the ESCC microenvironment into an immunologically active state via the GPX2-ICD-DC signaling path"],"prefix":"10.1186","volume":"24","author":[{"given":"Yu","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dashan","family":"Ai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengnan","family":"Hao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengtao","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8663-2874","authenticated-orcid":false,"given":"Kuaile","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,22]]},"reference":[{"issue":"3","key":"8323_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u201363.","journal-title":"CA Cancer J Clin"},{"issue":"11","key":"8323_CR2","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1007\/s11894-023-00899-0","volume":"25","author":"S Lander","year":"2023","unstructured":"Lander S, Lander E, Gibson MK. Esophageal cancer: Overview, risk factors, and reasons for the rise. Curr Gastroenterol Rep. 2023;25(11):275\u20139.","journal-title":"Curr Gastroenterol Rep"},{"issue":"2","key":"8323_CR3","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.radonc.2017.06.019","volume":"124","author":"M Xi","year":"2017","unstructured":"Xi M, Xu C, Liao Z, Hofstetter WL, Blum Murphy M, Maru DM, et al. The impact of histology on recurrence patterns in esophageal cancer treated with definitive chemoradiotherapy. Radiother Oncol. 2017;124(2):318\u201324.","journal-title":"Radiother Oncol"},{"issue":"1","key":"8323_CR4","doi-asserted-by":"publisher","first-page":"6268","DOI":"10.1038\/s41467-020-20019-0","volume":"11","author":"Y Zheng","year":"2020","unstructured":"Zheng Y, Chen Z, Han Y, Han L, Zou X, Zhou B, et al. Immune suppressive landscape in the human esophageal squamous cell carcinoma microenvironment. Nat Commun. 2020;11(1):6268.","journal-title":"Nat Commun"},{"issue":"4","key":"8323_CR5","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/S1470-2045(23)00060-8","volume":"24","author":"Y Zhu","year":"2023","unstructured":"Zhu Y, Wen J, Li Q, Chen B, Zhao L, Liu S, et al. Toripalimab combined with definitive chemoradiotherapy in locally advanced oesophageal squamous cell carcinoma (EC-CRT-001): a single-arm, phase 2 trial. Lancet Oncol. 2023;24(4):371\u201382.","journal-title":"Lancet Oncol"},{"issue":"39","key":"8323_CR6","doi-asserted-by":"publisher","first-page":"3641","DOI":"10.1038\/s41388-025-03560-4","volume":"44","author":"H Panda","year":"2025","unstructured":"Panda H, Rowland NG, Krall CM, Bowman BM, Major MB, Zolkind P. NRF2 immunobiology in cancer: implications for immunotherapy and therapeutic targeting. Oncogene. 2025;44(39):3641\u201351.","journal-title":"Oncogene"},{"issue":"1","key":"8323_CR7","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/s12929-022-00873-4","volume":"29","author":"CH Hsieh","year":"2022","unstructured":"Hsieh CH, Kuan WH, Chang WL, Kuo IY, Liu H, Shieh DB, et al. Dysregulation of SOX17\/NRF2 axis confers chemoradiotherapy resistance and emerges as a novel therapeutic target in esophageal squamous cell carcinoma. J Biomed Sci. 2022;29(1):90.","journal-title":"J Biomed Sci"},{"issue":"1","key":"8323_CR8","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1038\/s41467-017-01730-x","volume":"8","author":"J Deng","year":"2017","unstructured":"Deng J, Chen H, Zhou D, Zhang J, Chen Y, Liu Q, et al. Comparative genomic analysis of esophageal squamous cell carcinoma between Asian and Caucasian patient populations. Nat Commun. 2017;8(1):1533.","journal-title":"Nat Commun"},{"issue":"1","key":"8323_CR9","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1186\/s12935-022-02685-w","volume":"22","author":"Z Wang","year":"2022","unstructured":"Wang Z, Wu S, Zhu C, Shen J. The role of ferroptosis in esophageal cancer. Cancer Cell Int. 2022;22(1):266.","journal-title":"Cancer Cell Int"},{"issue":"7","key":"8323_CR10","doi-asserted-by":"publisher","first-page":"2347","DOI":"10.1245\/s10434-014-3600-2","volume":"21","author":"Y Kawasaki","year":"2014","unstructured":"Kawasaki Y, Okumura H, Uchikado Y, Kita Y, Sasaki K, Owaki T, et al. Nrf2 is useful for predicting the effect of chemoradiation therapy on esophageal squamous cell carcinoma. Ann Surg Oncol. 2014;21(7):2347\u201352.","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"8323_CR11","doi-asserted-by":"publisher","first-page":"12846","DOI":"10.1038\/s41598-018-31281-0","volume":"8","author":"MJ Kerins","year":"2018","unstructured":"Kerins MJ, Ooi A. A catalogue of somatic NRF2 gain-of-function mutations in cancer. Sci Rep. 2018;8(1):12846.","journal-title":"Sci Rep"},{"issue":"1","key":"8323_CR12","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1111\/nyas.13681","volume":"1434","author":"S Ma","year":"2018","unstructured":"Ma S, Paiboonrungruan C, Yan T, Williams KP, Major MB, Chen XL. Targeted therapy of esophageal squamous cell carcinoma: the NRF2 signaling pathway as target. Ann N Y Acad Sci. 2018;1434(1):164\u201372.","journal-title":"Ann N Y Acad Sci"},{"issue":"4","key":"8323_CR13","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1038\/s41590-022-01132-2","volume":"23","author":"G Kroemer","year":"2022","unstructured":"Kroemer G, Galassi C, Zitvogel L, Galluzzi L. Immunogenic cell stress and death. Nat Immunol. 2022;23(4):487\u2013500.","journal-title":"Nat Immunol"},{"issue":"2","key":"8323_CR14","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/nri.2016.107","volume":"17","author":"L Galluzzi","year":"2017","unstructured":"Galluzzi L, Buqu\u00e9 A, Kepp O, Zitvogel L, Kroemer G. Immunogenic cell death in cancer and infectious disease. Nat Rev Immunol. 2017;17(2):97\u2013111.","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"8323_CR15","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1186\/s12885-025-13801-0","volume":"25","author":"Z Yin","year":"2025","unstructured":"Yin Z, Zhang H, Zhang K, Yue J, Tang R, Wang Y, et al. Impacts of combining PD-L1 inhibitor and radiotherapy on the tumour immune microenvironment in a mouse model of esophageal squamous cell carcinoma. BMC Cancer. 2025;25(1):474.","journal-title":"BMC Cancer"},{"key":"8323_CR16","doi-asserted-by":"crossref","unstructured":"Korbecki J, Kojder K, Kapczuk P, Kupnicka P, Gawro\u0144ska-Szklarz B, Gutowska I, et al. The effect of hypoxia on the expression of cxc chemokines and CXC chemokine receptors-A review of literature. Int J Mol Sci. 2021;22(2).","DOI":"10.3390\/ijms22020843"},{"issue":"3","key":"8323_CR17","doi-asserted-by":"publisher","first-page":"791","DOI":"10.21037\/jgo-22-524","volume":"16","author":"J Zhou","year":"2025","unstructured":"Zhou J, Bao E, Wu G, Fan Q, Zhao Y, Zhang Y, et al. Efficacy and safety of concurrent radiotherapy and chemotherapy for locally advanced esophageal squamous cell carcinoma: a randomized controlled trial. J Gastrointest Oncol. 2025;16(3):791\u2013801.","journal-title":"J Gastrointest Oncol"},{"issue":"12","key":"8323_CR18","doi-asserted-by":"publisher","first-page":"2994","DOI":"10.1002\/1878-0261.12851","volume":"14","author":"A Ahmed","year":"2020","unstructured":"Ahmed A, Tait SWG. Targeting immunogenic cell death in cancer. Mol Oncol. 2020;14(12):2994\u20133006.","journal-title":"Mol Oncol"},{"issue":"7","key":"8323_CR19","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1038\/s41416-025-03113-2","volume":"133","author":"JM Ko","year":"2025","unstructured":"Ko JM, Guo C, Leung AK, Chan SC, Lo AW, Tao L, et al. Oncogenic NFE2L2 mutations in plasma ctDNA and tumors are predictors and prognosticators of chemoradiation therapy in resectable esophageal squamous cell carcinoma. Br J Cancer. 2025;133(7):1046\u201355.","journal-title":"Br J Cancer"},{"key":"8323_CR20","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3389\/fimmu.2017.00229","volume":"8","author":"E Wennerberg","year":"2017","unstructured":"Wennerberg E, Lhuillier C, Vanpouille-Box C, Pilones KA, Garc\u00eda-Mart\u00ednez E, Rudqvist NP, et al. Barriers to radiation-induced in situ tumor vaccination. Front Immunol. 2017;8:229.","journal-title":"Front Immunol"},{"issue":"17","key":"8323_CR21","doi-asserted-by":"publisher","first-page":"1774","DOI":"10.1089\/ars.2017.7356","volume":"29","author":"SB Lee","year":"2018","unstructured":"Lee SB, Sellers BN, DeNicola GM. The regulation of NRF2 by nutrient-responsive signaling and its role in anabolic cancer metabolism. Antioxid Redox Signal. 2018;29(17):1774\u201391.","journal-title":"Antioxid Redox Signal"},{"issue":"4","key":"8323_CR22","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.tibs.2014.02.002","volume":"39","author":"JD Hayes","year":"2014","unstructured":"Hayes JD, Dinkova-Kostova AT. The Nrf2 regulatory network provides an interface between redox and intermediary metabolism. Trends Biochem Sci. 2014;39(4):199\u2013218.","journal-title":"Trends Biochem Sci"},{"issue":"334","key":"8323_CR23","doi-asserted-by":"publisher","first-page":"334ra51","DOI":"10.1126\/scitranslmed.aad6095","volume":"8","author":"H Wang","year":"2016","unstructured":"Wang H, Liu X, Long M, Huang Y, Zhang L, Zhang R, et al. NRF2 activation by antioxidant antidiabetic agents accelerates tumor metastasis. Sci Transl Med. 2016;8(334):334ra51.","journal-title":"Sci Transl Med"},{"key":"8323_CR24","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.freeradbiomed.2015.02.004","volume":"83","author":"LK Sha","year":"2015","unstructured":"Sha LK, Sha W, Kuchler L, Daiber A, Giegerich AK, Weigert A, et al. Loss of Nrf2 in bone marrow-derived macrophages impairs antigen-driven CD8(+) T cell function by limiting GSH and Cys availability. Free Radic Biol Med. 2015;83:77\u201388.","journal-title":"Free Radic Biol Med"},{"issue":"1","key":"8323_CR25","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1186\/s12967-021-03042-7","volume":"19","author":"L Feng","year":"2021","unstructured":"Feng L, Zhao K, Sun L, Yin X, Zhang J, Liu C, et al. SLC7A11 regulated by NRF2 modulates esophageal squamous cell carcinoma radiosensitivity by inhibiting ferroptosis. J Transl Med. 2021;19(1):367.","journal-title":"J Transl Med"},{"issue":"1","key":"8323_CR26","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1186\/s12967-025-06468-5","volume":"23","author":"Y Tan","year":"2025","unstructured":"Tan Y, Yang L, Xu T, Wang Q, Huang M, Zhao Z, et al. GPX2 inhibition enhances antitumor efficacy of lenvatinib via promoting immunogenic cell death in hepatocellular carcinoma. J Transl Med. 2025;23(1):456.","journal-title":"J Transl Med"},{"issue":"1","key":"8323_CR27","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1111\/imr.12586","volume":"280","author":"Y Ma","year":"2017","unstructured":"Ma Y, Pitt JM, Li Q, Yang H. The renaissance of anti-neoplastic immunity from tumor cell demise. Immunol Rev. 2017;280(1):194\u2013206.","journal-title":"Immunol Rev"},{"key":"8323_CR28","doi-asserted-by":"publisher","first-page":"609","DOI":"10.3389\/fonc.2018.00609","volume":"8","author":"PG Tsoutsou","year":"2018","unstructured":"Tsoutsou PG, Zaman K, Martin Lluesma S, Cagnon L, Kandalaft L, Vozenin MC. Emerging opportunities of radiotherapy combined with immunotherapy in the era of breast cancer heterogeneity. Front Oncol. 2018;8:609.","journal-title":"Front Oncol"},{"key":"8323_CR29","doi-asserted-by":"publisher","first-page":"503","DOI":"10.3389\/fonc.2018.00503","volume":"8","author":"K Gupta","year":"2018","unstructured":"Gupta K, Burns TC. Radiation-induced alterations in the recurrent glioblastoma microenvironment: Therapeutic implications. Front Oncol. 2018;8:503.","journal-title":"Front Oncol"},{"issue":"3","key":"8323_CR30","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1038\/s43018-025-00918-1","volume":"6","author":"H Bando","year":"2025","unstructured":"Bando H, Kumagai S, Kotani D, Mishima S, Irie T, Itahashi K, et al. Atezolizumab following definitive chemoradiotherapy in patients with unresectable locally advanced esophageal squamous cell carcinoma - a multicenter phase 2 trial (EPOC1802). Nat Cancer. 2025;6(3):445\u201359.","journal-title":"Nat Cancer"},{"issue":"5","key":"8323_CR31","doi-asserted-by":"publisher","first-page":"e2201401","DOI":"10.1002\/smtd.202201401","volume":"7","author":"T Liu","year":"2023","unstructured":"Liu T, Pei P, Shen W, Hu L, Yang K. Radiation-induced immunogenic cell death for cancer radioimmunotherapy. Small Methods. 2023;7(5):e2201401.","journal-title":"Small Methods"},{"issue":"12","key":"8323_CR32","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1007\/s12032-024-02483-6","volume":"41","author":"L Yan","year":"2024","unstructured":"Yan L, Hu H, Feng L, Li Z, Zheng C, Zhang J, et al. ML385 promotes ferroptosis and radiotherapy sensitivity by inhibiting the NRF2-SLC7A11 pathway in esophageal squamous cell carcinoma. Med Oncol. 2024;41(12):309.","journal-title":"Med Oncol"},{"issue":"2","key":"8323_CR33","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1007\/s12032-025-03229-8","volume":"43","author":"L Zhao","year":"2026","unstructured":"Zhao L, Guo Y, Jian J, Tang X, An S, Niu Y, et al. Venetoclax combined with ML385 overcomes chemotherapy resistance in acute myeloid leukemia by modulating Nrf2\/ARE-mediated oxidative stress. Med Oncol. 2026;43(2):114.","journal-title":"Med Oncol"},{"key":"8323_CR34","doi-asserted-by":"crossref","unstructured":"Zhu Y, Liu M, Fan X, Xu Y, Diao X, Bi J, et al. Targeted inhibition of Nrf2 potentiates antitumor immunity and enhances the efficacy of immunotherapy in hepatocellular carcinoma. J Immunother Cancer. 2026;14(3).","DOI":"10.1136\/jitc-2024-010841"},{"key":"8323_CR35","doi-asserted-by":"publisher","first-page":"177935","DOI":"10.1016\/j.ejphar.2025.177935","volume":"1003","author":"S Qi","year":"2025","unstructured":"Qi S, Li D, Deng F, Fu S, Chen S, Zou H, et al. Brusatol modulates the Nrf2\/GCLC pathway to enhance ferroptosis in the treatment of oral squamous cell carcinoma. Eur J Pharmacol. 2025;1003:177935.","journal-title":"Eur J Pharmacol"},{"issue":"2","key":"8323_CR36","doi-asserted-by":"publisher","first-page":"114053","DOI":"10.1016\/j.yexcr.2024.114053","volume":"438","author":"X Yu","year":"2024","unstructured":"Yu X, He Z, Wang Z, Ke S, Wang H, Wang Q, et al. Brusatol hinders the progression of bladder cancer by Chac1\/Nrf2\/SLC7A11 pathway. Exp Cell Res. 2024;438(2):114053.","journal-title":"Exp Cell Res"},{"issue":"5","key":"8323_CR37","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1007\/s40618-023-02248-4","volume":"47","author":"Z Gong","year":"2024","unstructured":"Gong Z, Xue L, Vlantis AC, van Hasselt CA, Chan JYK, Fang J, et al. Brusatol attenuated proliferation and invasion induced by KRAS in differentiated thyroid cancer through inhibiting Nrf2. J Endocrinol Invest. 2024;47(5):1271\u201380.","journal-title":"J Endocrinol Invest"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-026-08323-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-08323-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-08323-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T13:43:19Z","timestamp":1782222199000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12967-026-08323-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,22]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8323"],"URL":"https:\/\/doi.org\/10.1186\/s12967-026-08323-7","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,22]]},"assertion":[{"value":"22 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The animal experiments received approval from the Animal Ethics Committee at Fudan Cancer research Institute Technology Platform (FUSCC-IACUC-2024136). All animal procedures were performed in strict accordance with the International Guide for Animal Research Reporting (ARRIVE 2.0).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"805"}}